APTX Aptinyx Inc.

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders.

$2.15
As of 12/03/2021     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/21/2018
Outstanding shares:  67,715,718
Average volume:  163,155
Market cap:   $154,391,837
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    03836N103
ISIN:        US03836N1037
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   -2.63
PB ratio:   1.30
PS ratio:   25.41
Return on equity:   -59.59%
Net income %:   -1,099.01%